

Anti-CTLA-4 (Ipilimumab), Humanized Antibody

rev 01/21

CATALOG NO.: A2110-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a fully-humanized IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). By binding to CTLA-4, it releases the inhibitory action on cytotoxic T-lymphocytes and thus destroys cancer cells. The original monoclonal antibody is approved by the FDA to treat metastatic melanoma, metastatic colorectal cancer, and hepatocellular carcinoma. The antibody is also recommended in combination therapy with Nivolumab for advanced renal cell carcinoma

ALTERNATE NAMES: CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3, CTLA4

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: CHO cells / Human IgG1

IMMUNOGEN: Ipilimumab

CAS NUMBER: 477202-00-9

MOLECULAR WEIGHT: 148 kDa

FORM: Liquid

FORMULATION: In PBS buffer, pH 7.2

STORAGE CONDITIONS: Undiluted antibody solution should be stored at 4°C in the dark and avoid freezing the solution

APPLICATIONS AND USAGE: Cell proliferation assay, *In vivo* studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

Anti-PD-L1 (Atezolizumab), Humanized Antibody (A1305)

Anti-CTLA4 Antibody (A1083)

FOR RESEARCH USE ONLY! Not to be used on humans.